We are proud to announce that we have received this prestigious “Børsen Gazelle Award” for the second time.

To receive the Gazelle Award, a company must be among the most successful companies across all industries in Denmark. Have demonstrated positive growth and have doubled revenue over a period of four financial years. The growth measure is based on net sales. If this is not disclosed in the annual report, the gross profit is used instead. 

We are excited to accept this prestigious award and would like to thank Børsen for this acknowledgement.

DICOM - A REALITY IN DIGITAL PATHOLOGY WORKFLOWS

October 2, 2017

Just as for other medical fields, DICOM is expected to play a significant role in pathology as a universal and fundamental standard in digital medical imaging. The value chain of solution components in a digital pathology lab is both long and complex, which makes the adoption of standards as DICOM all the more important.

"One of the visions driving DICOM in general is to give users the freedom to choose the best-of-breed solution components, rather than being tied to single vendor", says Mikael Wintel who has been one of the driving forces behind the adaptation of the DICOM standard to the digital pathology field, through his work as co-chair of Working Group 26. Mikael Wintell is also panelist at the upcoming DICOM Digital Pathology Connect-a-thon at Pathology Visions.

Read more

Neagen and Visiopharm announce new Technical Integration between image analysis and PACS to meet demands from pathologists

 

Hørsholm – Denmark, September 5th, 2017 - Neagen and Visiopharm today announce an integration which improves the data quality of cancer patient samples in a single PACS-driven digital pathology workflow also offering time and cost savings. This in term enhances quality for pathologists working in cancer research and diagnostics and benefits the patients.

Visiopharm is a worldwide leader of Augmented Pathology™ within tissue research and diagnostics and Neagen offers a true vendor neutral enterprise imaging system based on worldwide DICOM standard.

“We are excited to see an increased demand for both workflow automation and improved interpretive accuracy from pathologists in Finland. These are the two areas where Visiopharm makes a real difference. By integrating our Augmented Pathology™ software with neaLink, customers can now integrate precision pathology into PACS-driven workflows, to achieve better data quality, turnaround times, and reduce manual labor”, says Michael Grunkin, CEO Visiopharm.

“Neagen sees digital pathology as indispensable in the modern pathology lab, and seamless integration into other existing diagnostic medical workflows is a pivotal requirement to successful deployment. neaLink VNA is a modern and scalable enterprise imaging solution for all medical disciplines. With this technical integration, our customers across the globe will be able to combine advanced image analysis to digital pathology with radiology in a seamlessly integrated digital workflow, to further enhance neaLink as a platform for integrated diagnostics”, says Lasse Jyrkinen, CEO Neagen.

The Oncotopix® solution is compatible with and validated for all major scanner formats, and has been validated and CE-marked for the three major reagent vendors. Making Oncotopix® available as a simple and seamlessly integrated plug-in to PACS and LIS systems, makes it possible to deploy and scale digital pathology in the lab, one cost-efficient and risk-free step at a time.

For further information, please contact:

Lasse Jyrkinen, CEO

Neagen Oy

Tel: +358 40 539 3163

E-mail: lasse.jyrkinen@neagen.com

Helle Fisker, CMO

Visiopharm A/S

Tel: +45 29178777

Email: hfi@visiopharm.com

 

 

About Neagen

Neagen is a true pioneer in the enterprise imaging by supporting fully digital workflow for all the medical specialties. Company is dedicated to support storing and distributing all medical images, videos and reports according to the DICOM standard since 2003.

Neagen has invested a lot in developing a true vendor neutral archive approach (VNA) and are proud that when receiving incoming data, regardless of it’s format Neagen software will automatically convert this to DICOM format. This innovative feature means patient data can not only be stored for longer, it can also be viewed and/or distributed in optical condition during this period - something that most medical devices and IT systems cannot guarantee. Neagen's digital pathology solution is a continuation of our vision, thus there is no compromises on workflow efficiency or conformance with the standards.

Neagen is a privately-owned company and has its headquarter in Helsinki, Finland and R&D facility in Oulu, Finland.

About Visiopharm

Visiopharm is a vendor-neutral provider of Augmented Pathology comprising high throughput and precision pathology for digital and automated test applications. Through its many partnerships and expertise in intelligent image analysis Visiopharm solutions span across the entire digital pathology workflow modernising and improving anatomic pathology laboratory routines worldwide. In EU Visiopharm offers several IVD algorithms as an aid to the pathologists doing breast cancer diagnostics. Recently Visiopharm launched a new Viewer completely innovating smooth and seamless navigation for routine analysis.

Visiopharm’s software is featured in over 1200 scientific publications, and has over 800 licenses placed, with countless users, in more than 30 countries. Headquartered in the Medicon Valley of Denmark, with a branch office in Sweden, the Netherlands, and North America in Broomfield, Colorado.

Hørsholm, Denmark, May 3rd - Visiopharm A/S announces the first result of their multifaceted strategy to apply Deep Learning technologies to its leading image analysis solution for cancer research and diagnostics. Visiopharm considers Deep Learning an important technological breakthrough for tissue pathology that offers the potential to make a real difference in the assessment of tissue structures, which is probably one of the most complex and challenging applications of image analysis.

Real progress in this field requires a multi-disciplinary approach and therefore Visiopharm has established a broad multidisciplinary strategy to lead further development of Deep Learning in tissue pathology, within several important clinical and research applications.  To support this strategy Visiopharm has established an International Consortium for Deep Learning in Tissue Pathology. The consortium involves Academic Medical Centers, Tissue Biobanks, Engineering Universities, Biopharmaceutical companies, and other industrial partners who all share this vision.  “We are very excited about our fast progress in deep learning over the past year and Visiopharm remains committed to investing a lot more in this technology .  We are currently formalizing the consortium and we look forward to continued collaborations and sharing more details on this initiative soon” says Michael Grunkin, CEO of Visiopharm.  

Read more